- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06388954
Plasticity Biomarkers,Interleukin-6 and Motor Performance in Response to Vagus Nerve Stimulation After Stroke
Neural-Plasticity Biomarkers, Interleukin-6 and Motor Performance in Response to Non-Invasive Vagus Nerve Stimulation After Stroke: A Randomized Controlled Clinical Trial
Study Overview
Status
Conditions
Detailed Description
Background: Neuromodulation techniques play an integral role in restoring motor function in stroke patients by affecting the adaptive neuroplasticity and activation of neuromodulators that may reduce brain inflammation post stroke.
Objective: To assess the efficacy of transcutaneous auricular vagal nerve stimulation on plasma levels of Brain-Derived Neurotrophic Factors (BDNF), Interleukin-6 (IL-6), gross manual dexterity, and muscle tone in patients with ischemic stroke.
Materials and Methods: Forty-eight clinically verified Egyptian patients from both sexes with ischemic stroke that occurred at least 6 months to 2 years before inclusion, aged 55 to 65 years, were recruited. Patients will be randomly assigned into two equal groups; control group (GA) and the experimental group (GB). Patients in the control group (GA) were treated with sham Vagus nerve stimulation (taVNS) immediately before a selected physical therapy program, while in the experimental group (GB), patients received real transcutaneous auricular Vagus nerve stimulation (taVNS) followed by the same selected physical therapy program as (GA). Plasma levels of Brain-Derived Neurotrophic Factors (BDNF), serum Interleukin-6 (IL-6) , Box and Blocks Test (BBT) and Modified Ashworth scale (MAS) were assessed at baseline and immediately post-treatment.
Results: There was a statistically significant improvement in BBT, plasma IL-18 level and BDNF in experimental group (GB) post-treatment (P< 0.05) with no change in MAS. There was no statistical significant difference in BBT, plasma Interleukin-6 (IL-6) and MAS in control group post treatment (P> 0.05). While, there is a statistically significant improvement in BDNF in the control group post treatment. A statistically significant improvement was observed of BBT and BDNF in the study group compared to the control group (P< 0.05). There was no statistical significant difference in MAS between study and control groups (P> 0.05).
Conclusions: Non-invasive VNS as an adjunct to conventional physical rehabilitation enhances neuroplasticity and improves upper limb motor ability after ischemic stroke, as well as reducing the stroke-induced inflammatory process, which may affect the disease prognosis.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Moshera H. Darwish, PhD
- Phone Number: 00201015163617
- Email: dr.moshera11@yahoo.com
Study Contact Backup
- Name: Engy B Saleh, PhD
- Phone Number: 00201099445112
- Email: engybm.saleh@yahoo.com
Study Locations
-
-
Ad Doqi, Giza District, Giza Governorate
-
Giza, Ad Doqi, Giza District, Giza Governorate, Egypt, 11432
- Recruiting
- Faculty of Physical Therapy, Cairo University
-
Contact:
- Engy BadrEldin S Moustafa, PhD
- Phone Number: 00201099445112
- Email: engybm.saleh@cu.edu.eg
-
Contact:
- Moshera H. Darwish, PhD
- Phone Number: 00201015163617
- Email: dr.moshera11@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hemiparetic patients with ischemic middle cerebral artery stroke
- The duration of illness ranged from at least 6 months to 2 years after stroke.
- Patient's age ranged from 55 to 65 years, patients with unilateral upper limb motor function impairment.
- Patients able to transfer at least one block in Box and Blocks Test.
- Patients with sufficient cognitive abilities that enables them to understand and follow instructions.
- Spasticity of upper limb muscles ranged from (grade 1:2) according to Modified Ashworth scale.
Exclusion Criteria:
- Other neurological diseases that affect upper limb function other than stroke (e.g.: Multiple sclerosis, peripheral neuropathy, Parkinsonism….etc.).
- Hemorrhagic stroke
- Visual or auditory impairment affecting their ability to complete the testing.
- Cognitive impairment.
- Cardiovascular problems and pulmonary or kidney disorders
- Musculoskeletal disorders (e.g. scoliosis, kyphosis, severe arthritis…etc.)
- Severe spasticity (a Modified Ashworth Scale score ≥3).
- Patients with any taVNS contraindications such as previous surgical intervention on Vagus nerve.
- Low blood pressure (<100/60mmHg) or low heart rate (<60bpm) and or high blood pressure (>220/130 mmHg).
- Pacemaker or other implanted electrical device.
- Any current or past history of cardiovascular disorders
- Facial or ear pain
- Recent ear trauma .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control group (GA)
Patients in the control group (GA) will be treated by 12 sessions of sham transcutaneous auricular Vagus nerve stimulation for 30 minutes immediately, will be followed by 30 minutes of a selected physical therapy program, three sessions per week for four consecutive weeks.
Sham transcutaneous vagal nerve stimulation was performed using the same procedures as the study group but without electrical stimulation.
|
Sham transcutaneous vagal nerve stimulation will be performed by the same procedures of the study group but without electrical stimulation.
The active electrodes will be attached to the left cymba conchae.
The taVNS stimulator will be turned on and the stimulation intensity will be increased until the patient perceived the electrical stimulation and then the stimulator will be turned off.
|
Experimental: Study group (GB)
Patients in the study group (GB) will be treated by 12 sessions of true transcutaneous auricular Vagus nerve stimulation for 30 minutes , then immediately followed by 30 minutes of a selected physical therapy program (GA), three sessions per week for four consecutive weeks.
The stimulation of the auricular branch of the Vagus nerve will be performed by conventional TENS device with one channel and two electrodes.
|
Vagus Nerve Stimulation (VNS) consists in the activation of the Vagus nerve using electrical current, Transcutaneous auricular VNS works through the placement of noninvasive electrodes on the neck or auricle for stimulation of the auricular branch of the vagus nerve. Transcutaneous electrical nerve stimulation (TENS) electrodes will be used to stimulate the auricular branch of the Vagus nerve, The active electrode will be placed on the cymba concha of the left ear. This reduced the risk of taVNS side effect on the heart. The reference electrode will be placed outside the left ear attached to the tragus. TENS parameters used were: 30 minutes treatment time, a pulse width of 300 microseconds, pulse frequency 20 hertz and a duty cycle of 25%. The stimulation intensity was set at super-threshold levels, such as 200% of patient perceptual threshold.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle tone of the upper limb
Time Frame: Baseline Assessment and Immediately Post Treatment.
|
The Modified Ashworth Scale (MAS) will be used; it is a six-point ordinal scale.
It ranges from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension).
The muscle tone was measured by observing the response of the muscle group to the resistance of passive movement in the affected hand.
The degree of muscle tone in the affected hand was classified as (0 = normal, 1 or 1+ = mild, 2 or 3 = moderate, or 4 = severe).
|
Baseline Assessment and Immediately Post Treatment.
|
Gross hand dexterity
Time Frame: Baseline Assessment and Immediately Post Treatment.
|
The Box and Blocks Test (BBT) will be used; it is a quick, simple, and inexpensive test for measuring unilateral gross manual dexterity in stroke.
The patients were asked to transfer as many blocks as they could from one compartment to the other for 60 seconds.
The patient was allowed to choose any block of any color and to carry only one block each time with his hand, which must cross over the partition.
|
Baseline Assessment and Immediately Post Treatment.
|
Level of Plasma brain-derived Derived factor (BDNF)
Time Frame: Baseline Assessment and Immediately Post Treatment.
|
Sandwich-ELISA kits will be used according to the manufacturer's instructions.
Venous blood samples were collected in a disposable plastic vacuum tube with an anticoagulant.
Samples were centrifuged for 15 min at 1000×g at 2-8 °C within 30 min of collection.
|
Baseline Assessment and Immediately Post Treatment.
|
Level of Serum Interleukin IL-6
Time Frame: Baseline Assessment, Immediately Post Treatment, 3 Month Posttreatment Assessment (Follow-up)
|
Interleukin-6 (IL-6) is a crucial inflammatory factor in that its significant increase was observed in stroke patients shortly following the ischemic event and serves a vital role as a messenger molecule between leucocytes, the vascular endothelium, and parenchyma.
A single referral lab will test the samples using ELISA and U/CyTech kits.
From each participant, 10 milliliters of non-fasting blood sample will be obtained 6 to 24 hours after the onset of symptoms and kept in citrate tubes.
Blood samples will thereafter centrifuged within 1 hour at 3000 × g for 15 minutes at 4°C and resultant plasma will be kept in -80°C.
|
Baseline Assessment, Immediately Post Treatment, 3 Month Posttreatment Assessment (Follow-up)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Engy B Saleh, PhD, Faculty of Physical Therapy, Cairo University, Egypt
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P.T.REC/012/005107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Sham Trancutaneous auricular Vagus Nerve Stimulation
-
University Hospital, GrenobleRecruiting
-
Anna HuguenardRecruiting
-
İSMAİL CEYLANCompleted
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden
-
Jiani WuNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityBrainClos Co., LTD.; Zhuhai Fudan Innovation InstituteNot yet recruitingCluster Headache | Migraine in Children | Tension Headache | Migraine in Adolescence | Primary HeadacheChina
-
Guang'anmen Hospital of China Academy of Chinese...China Association for Science and TechnologyRecruiting
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingParkinson DiseaseChina
-
Burrell College of Osteopathic MedicineRecruitingPsoriasis VulgarisUnited States